Ganglion Cysts
Conditions
Brief summary
Digital myxoid cysts arise from degeneration in the connective tissue of the digit joint, usually the last joint of the finger or toe, often due to underlying joint arthritis. They may connect with the joint. Pressure from the cyst can result in deformity of the digit's nail and trauma to the cyst results in leakage of the fluid, representing a potential source of entry for infection. Cysts can be tender and interfere with the digit's function. A variety of treatments are available, from simple extrusion which is rarely successful, to more destructive cryotherapy, infra-red coagulation and formal excision under local anaesthetic. These latter three approaches can result in considerable scarring. Sclerosant injection of polidocanol in one small non-randomised trial has been reported to be a well tolerated efficacious treatment with minimal scarring and long-term resolution. Following a pilot study, the investigators aim to trial this treatment to assess efficacy in a larger population.
Interventions
Sponsors
NHS Lothian
Foundation for Skin Research
University of Edinburgh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All patients referred to dermatology in NHS Lothian or NHS Fife who have a visible Digital Myxoid Cyst affective the dital phalynx of the toes or fingers. * The patient must have the ability to give informed consent
Exclusion criteria
* History of sensitivity to polidocanol or other sclerosants * Age less than 18 * Inability to give informed consent * Inability to report side effects experienced * Cyst not clearly visible * Cyst not fluid-filled
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cyst resolution at 6 weeks | 6 weeks | Is there a difference in the percentage of participants with cyst resolution at 6 weeks post treatment in those treated with polidocanol compared to those treated with the current conventional treatments of cryotherapy and infra-red coagulation? |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cyst resolution at 12 and 52 weeks | 1 year | In those participants treated with polidocanol compared to cryotherapy and also compared to infra-red coagulation is there a difference in the percentage of participants with cyst resolution at 12 and 52 weeks post initial treatment |
| difference in scarring | 1 year | In those participants treated with polidocanol compared to cryotherapy and also compared to infra-red coagulation is there a difference in clinically apparent scarring |
| pain scores on a visual analogue scale | 1 year | In those participants treated with polidocanol compared to cryotherapy and also compared to infra-red coagulation is there a difference in procedure pain/discomfort |
| procedure satisfaction on a visual analogue scale | 1 year | In those participants treated with polidocanol compared to cryotherapy and also compared to infra-red coagulation is there a difference in procedure satisfaction |
Countries
United Kingdom
Outcome results
None listed